Oculus initiates Microcyn hydrogel study
The study is designed to recruit 40 patients at four different US sites and provide top-line data by mid-2013 calendar year. Oculus Innovative’s dermatology partner, AmDerma/Quinnova, has agreed
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
The current Phase 2 AbGn-168H trial will be a multicenter, placebo-controlled, double-blind trial with the primary objective to demonstrate that AbGn-168H provides safe, durable, and remissive therapeutic effect